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Abstract
Introduction: Multimorbidity (MM) by age groups curves be-
haviour and its relationship with disease severity are not well 
established. Considering the Charlson Index as a prognosis 
instrument to measure disease severity, the objectives were 
to characterise the MM and its severity through the Charlson 
index in Portuguese inpatients. Methods: A cross-sectional, 
descriptive study with an analytical component was drawn 
through data exported from the hospitalisations Homoge-
neous Diagnostic Groups database of the Portuguese-NHS 
during the year 2015. The study included 22 chronic health 
conditions: the 15 predicted in the Charlson index and 7 
more (hypertension, obesity, dyslipidaemia, osteoarthritis, 
osteoporosis, anxiety and depression). The bi and multivari-
able analyses were performed through the generalised lin-
ear model considering binary logistic regression. In the anal-
ysis, the IBM SPSS version 24.0 tool was used. Results: A total 
of 800,376 hospitalisations were analysed, from which 42% 
(336,398) corresponds to males and 58% (463,978) to fe-
males. The average age of the sample was 59.8 years, being 
higher in men (62.34 years) than in women (57.95 years). The 
mean number of diagnostics per person was 1.6, being 
greater in men (1.8). Disease severity was also higher in 
males. The greatest disease severity (Charlson > 5) occurred 
at middle-aged (between 55 and 74 years). Throughout life 
behaviour of the average number of conditions and the av-
erage Charlson index without adjustment for age is similar. 
By the weight attributed to age, the Charlson index age-ad-
justed shows a sharper tendency of elevation after the forty 
years. The distribution by age groups of the age-adjusted 
Charlson index, categorised according to the cut-offs de-
fined in the methodology (cut-off 0 to < 5; cut-off 5 to < 9; 
cut-off ≥9), showed an abrupt growth for the cut-off ≥9 at 
55/59 years, peaking at 75/79 years, while for cut-off 5 at < 9 
the most marked growth occurs at 65/69 and the peak about 
5 years later than for the cut-off ≥9. After the 90 years old all 
measures averages (MM and severity disease) suffer a de-
cline. Discussion: The results suggest that the greatest dis-
ease severity are male associated and occurred at middle 
ages. There was an association between any MM measure 
and the Charlson index. The MM curves behaviour showed a 
decline in nonagenary age, suggesting healthy people live 
longer. Questioned if the MM and its severity is not a middle 
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age health issue. As limitations, we identified its cross-sec-
tional design and the omission of socioeconomic informa-
tion and the use of the same medical conditions to measure 
MM and disease severity. Other studies and analysis models 
should explore the complexity of the MM phenomenon and 
its impact on long life.
© 2019 The Author(s) Published by S. Karger AG, Basel  
on behalf of NOVA National School of Public Health
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Palavras Chave
Multimorbilidade · Comorbilidade · Carga de doença · 
Gravidade da doença
Resumo
Introdução: A relação entre magnitude e gravidade da 
multimorbilidade, por grupos etários, não está bem esta-
belecida. Considerando o índice de Charlson como um in-
strumento de prognóstico para medir a gravidade da mul-
timorbilidade, os objetivos foram caracterizar a magni-
tude e gravidade da multimorbilidade em pacientes 
internados em Portugal. Métodos: Estudo transversal, de-
scritivo, com um componente analítico, elaborado a partir 
de dados exportados da base de dados de Grupos de Di-
agnósticos Homogéneos de internamentos hospitalares 
do SNS durante o ano de 2015. O estudo incluiu 22 
condições crónicas de saúde: as 15 previstas no índice de 
Charlson e mais sete (hipertensão, obesidade, dislipi-
demia, osteoartrose, osteoporose, ansiedade e de-
pressão). A análise bi e multivariada foi realizada através 
do modelo linear generalizado, considerando a regressão 
logística binária. Na análise, foi usada a ferramenta IBM 
SPSS versão 24.0. Resultados: Foram analisadas 800’376 
internamentos, das quais 42% (336’398) correspondem a 
homens. A idade média da amostra foi de 59,8 anos, sen-
do superior nos homens (62,34 anos) em relação às mul-
heres (57,95 anos). O número médio de diagnósticos por 
pessoa foi de 1,6, sendo maior nos homens (1,8). A gravi-
dade da doença também foi maior no sexo masculino. A 
maior gravidade da doença (Charlson > 5) ocorreu na me-
ia-idade (entre 55 e 74 anos). Por grupos etários, o com-
portamento do número médio de condições e do índice 
médio de Charlson sem ajuste para a idade é semelhante. 
Pelo peso atribuído à idade, o índice de Charlson ajustado 
à idade mostra uma tendência mais acentuada de eleva-
ção após os quarenta anos. A distribuição por faixa etária 
do índice de Charlson ajustado à idade, categorizada de 
acordo com os pontos de corte definidos na metodologia 
(ponto de corte 0 a < 5; ponto de corte 5 a < 9; ponto de 
corte ≥9), mostrou crescimento abrupto para o ponto de 
corte ≥9 aos 55/59 anos, com um pico aos 75/79 anos, 
enquanto para o ponto de corte 5 aos < 9 o crescimento 
mais acentuado ocorre aos 65/69 e o pico cerca de 5 anos 
mais tarde do que para o ponto de corte ≥9. Após os 90 
anos, todas as médias das medidas de multimorbilidade 
(magnitude e gravidade) sofrem um declínio. Discussão: 
Os resultados sugerem que a maior gravidade da doença 
está associada ao sexo masculino e ocorreu na meia-
idade. Houve associação entre qualquer medida de mul-
timorbilidade e o índice de Charlson. O comportamento 
das curvas de multimorbilidade mostrou um declínio nos 
nonagenários, sugerindo que as pessoas saudáveis vivem 
mais tempo. Questionando-se se a gravidade da multi-
morbilidade não é um problema de meia-idade. Como 
limitações, identificou-se o delineamento transversal e a 
omissão de informações socioeconómicas, o uso das mes-
mas condições médicas para medir a magnitude e a gra-
vidade da multimorbilidade. Outros estudos e modelos 
de análise devem explorar a complexidade do fenomeno 
da multimorbilidade e seu impacto ao longo da vida.
© 2019 The Author(s). Published by S. Karger AG, Basel 
on behalf of NOVA National School of Public Health
Introduction
The multimorbidity (MM) prevalence estimates are 
influenced by their operational definition (2 or more 
problems) and by the number of diagnoses defined [1, 2]. 
When considering a smaller number of diagnoses (5 di-
agnoses), a lower prevalence value is reported (0.3% at age 
32.5 years and 3.5% at 75 years) regardless of the sample 
size [2]. Conversely, when more diagnoses are consid-
ered, a higher prevalence is reported, which gives consis-
tency to the statement: differences in prevalence esti-
mates are by the number of chronic diseases considered 
[2]. The frequency of MM, as reported, varies according 
to the measure considered: 43.7% for 2 or more diagnoses 
(MM2 +), 27.4% (MM3 +), 14.7%, 7% (MM5 +) and 2.8% 
for 6 or more coexisting diagnoses (MM6 +) [3]. Finally, 
the MM prevalence curve estimates, by age, have different 
behaviours according to definitions 2 or more (MM2 +) 
and 3 or more (MM3 +) chronic diseases. MM2 + increas-
es rapidly until the age group 70–79 years and remains 
stable in the older age groups. MM3 + increases later (be-
tween 30–39 and 40–49 years old) with plateau up to 80–
89 years [3]. According to the meta-analysis of Violan et 
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al. [4], there is MM association with age and gender, de-
spite the latter not be consistent.
In a Portuguese study, carried out in the primary 
health-care context, in the adult population, nine out of 
10 participants (87.0%) had at least one chronic health 
problem, with a general average of 3.4 (3.6 men, 3.3 in 
women) [5]. The MM measured as MM2 + was present 
in 72.7% of the sample and if the measure was MM3 + was 
57.2% [5]. There was a significant (p < 0.05) association 
between MM and: male gender, age, living in rural areas, 
living alone, having low social status (schooling and in-
come) [5]. Which confirms the results of other studies, 
which showed an association between MM and lower so-
cial gradients [4–6].
Indexes were developed based on the number and the 
medical conditions severity, resulting in an added value. 
Of these, the Charlson index is one of the most widely 
used [7] and considered the most potent [8]. The Charl-
son index was developed based on the relative risk of 
death. The disease severity is measured by the morbidities 
impact on the overall morbidity (e.g., weighting of 6 for 
solid metastatic tumour, 2 for diabetes with complica-
tions) [9, 10].
The Charlson index allows us to measure comorbidity 
(e.g., index of 3 or more points means severe comorbid-
ity) and predict mortality (e.g., index of 5 or more points 
is a predictor of death at 3 years in 85% of patients) [9]. 
The Charlson index can, therefore, be considered a prog-
nostic health instrument for measuring the disease sever-
ity [10–13]. With advances in medicine and increased 
survival rates, health problems such as coronary heart 
disease, uncomplicated diabetes, or cerebrovascular dis-
ease were not associated with mortality [10]. However, 
the confirming change in prognosis did not justify any 
change in the Charlson index [10].
MM still seems to condition life expectancy [7]. In an 
outpatient retrospective cohort of MEDICARE beneficia-
ries between 2007 and 2008, a 67-year-old individual with 
no chronic conditions is expected to live on average 22.6 
more years, while the presence of 5 chronic diseases re-
moves 7.7 years in the average expected life. The median 
decline in life expectancy was 1.8 years for each addition-
al chronic condition – ranging from 0.4 years less for the 
first condition to 2.6 years less for the sixth diagnosis [7]. 
A study has compared MM pattern by age in a 9-year 
retrospective cohort of inpatients discharged. The mid-
dle-aged discharged in-patients with MM are admitted 
more often than olders and have similar total hospitalized 
days per year [14]. The Charlson Index is a prognostic 
tool that can measure disease severity [10–13]. It is im-
portant to know if there is an association between both 
(MM and severity of disease) considering the diagnoses 
and age group.
In this study, it was defined as objective to know the 
inpatients MM in the Portuguese NHS hospitals. An ad-
ditional aim was to assess the behaviour of the curves by 
age groups, through the count (magnitude) and Charlson 
index score (severity).
Methods
A cross-sectional, descriptive study with analytical component 
was drawn from data exported from the Homogeneous Diagnostic 
Groups (GDH) database.
GDH is a Portuguese classification system of admission pa-
tients in acute hospitals. That aggregate patients into clinically co-
herent and similar groups from resource consumption. It allows 
defining operationally the hospital products, which are the set of 
goods, and services that each patient receives according to their 
needs and the pathology that led to their hospitalisation. It allows 
identifying the diagnoses by admission episode and per patient.
The Charlson index has been widely used in health outcome 
studies to allow valid comparisons and adjustment to risk. Risk 
adjustment is a complex construction involving patient socio-
demographic factors (e.g., age), acute clinical stability, or disease 
severity and was created as an indicator of illness severity [15, 16]. 
There has been growing interest in the use of databases to study, 
and the Charlson index applied to administrative data coded ac-
cording to 9th version of the International Classification of Dis-
eases (ICD-9) [16].
In order to determine the disease severity through the Charlson 
index, the 15 identified diagnoses there (diabetes and hepatic in-
sufficiency have 2 levels of severity) to which were added the most 
prevalent problems (hypertension, obesity, dyslipidaemia, osteo-
arthritis, osteoporosis, anxiety and depression) [5, 17] making a 
total of 22 diagnoses (Fig. 1). After defining the diagnoses to be 
analysed, the respective codes were identified in the ICD-9, the 
classification used in the GDH (Table 1).
From the GDH database corresponding to hospitalisation epi-
sodes, during the year 2015, sociodemographic data (age and sex) 
and the 22 diagnoses according to CID9 codes (Table 1) were ex-
tracted for each episode.
The data were exported to an excel matrix and later to the IBM 
SPSS statistical tool version 24.0 for the Mac OS operating system, 
which supported the data analysis.
From the exported data, the paediatric population (0 to < 18 
years) was withdrawn. Given that a patient may have 1 or more 
admissions in 1 year, from the adult population (aged 18 or over) 
duplicates were removed. About the duplicates, the considered ep-
isode was the last. 
The 22 diagnoses had binary corresponding, the value 1 to 
the condition presence and 0 to the absence. The number of prob-
lems per person corresponded to the sum of the medical condi-
tions present. MM was determined according to the definitions of 
coexistence of 2 or more diagnoses (MM2 +) up to eight or more 
(MM8 +).
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The Charlson cumulative index was calculated considering the 
weight attributed to the diagnoses in the scale (Table 1). This index 
provides for adjustment for age by a weighting: 1 for group 40 at 
< 50 years; 2 for those aged 50 to < 60 years; 3 to that of 60 to < 70; 
and 4 to that of 70 and over.
The descriptive analysis took into account the age, the number 
of problems per person and the Charlson index as numerical vari-
ables. Quantitative variables were categorised to facilitate analysis:
1. Age groups: young adults, adults, pre-retirement adults, re-
tired seniors and oldest, or at 5-year intervals from 20 years to 95, 
or 10-year intervals from 35 onwards.
2. Total problems per person: according to the definitions of 
MM, 2 or more problems per person (MM2 +) up to eight or more 
(MM8 +).
3. Charlson index by severity: (cut-off 0 to < 5; cut-off 5 to < 9; 
cut-off ≥9) if calculated with adjustment for age or (cut-off < 5; cut-
off ≥5) without age adjustment.
The binary nature of the variables permits, the bi and multi-
variate analyses using the generalised linear model considering bi-
nary logistic regression.
Ethical Requirements
The GDH database, with encrypted personal identification 
data, is made available to ENSP students upon request for superior 
permission and confidentiality commitment.
The study protocol was submitted to the ARSLVT Ethics Com-
mittee for Health, which obtained a favourable opinion.
Results
From the GDH database, 1,026,317 episodes were ex-
ported, of which 136,574 corresponded to episodes refer-
ring to the paediatric population (0 to < 18 years). Epi-
sodes attributable to adults were 889,743 of which dupli-
cates were removed, with the aim of each person 
corresponding to an episode (the latter) as referred to in 
the methodology. About 10% of the episodes were re-
moved for duplication, considering 800,382 episodes for 
analysis and 6 missing for sex were excluded. For this rea-
son, 800,376 cases were analysed, corresponding 42% 
(336,398) to males and 58% (463,978) females. The aver-
age age of the sample was 59.8 years, being higher in the 
men sex (62.34 years, being 57.95 for the women sex).
To better understand the distribution, by age group 
and sex, of individuals who had at least 1 hospital stay in 
a public hospital during the year 2015, the data were sum-
marised in Table 2.
As can be observed, there is a predominance of females 
in all ages, except for the group designated as the third age 
group (aged 65–74), in which 51% were males.
The mean number of problems per patient was 1.6 
higher in men (1.8) than in women, which was 1.44. The 
severity of disease through the Charlson index was also 
0
1
2
3
4
5
6
7
Average medical conditions Average Charlson index Average Charlson index age-adjusted
18–19 20–24 25–29 30–34 35–39 40–44 45–49 50–54 55–59 60–64 65–69 70–74 75–79 80–84 85–89 90–94 95–99 100+
Fig. 1. Distribution of the means of different MM measures by age groups.
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Table 1. Correspondence between diagnoses and ICD-9 codes
Medical condition Weighting ICD-9
Ischemic coronary artery 
disease
1 410 410.00 410.01 410.02 410.10 410.11 410.12 410.2 410.20 410.21 410.22 410.3 410.30 410.31 410.32 410.4 
410.40 410.41 410.42 410.5 410.50 410.51 410.52 410.6 410.60 410.61 410.62 410.7 410.70 410.72 410.8 410.80 
410.82 410.9 410.90 410.91 410.92
Congestive heart failure 1 428 428.0 428.1 428.2 428.20 428.21 428.22 428.23 428.3 428.30 428.31 428.32 428.33 428.4 428.40 428.42 
428.43 428.9
Peripheral vascular disease 1 440 440.0 440.1 440.2 440.20 440.21 440.22 440.3 440.30 440.31 440.32 440.4 440.8 440.9 441 441.0 441.00 
441.01 441.02 441.3 441.1 441.2 441.4 441.5 441.6 441.7 441.9 442 442.0 442.1 442.2 442.3 442.8 442.81 442.82 
442.83 442.84 442.89 442.9 443 443.0 443.1 443.2 443.21 443.22 443.23 443.24 443.29 443.8 443.81 443.82 
443.89 443.9
Cerebrovascular disease 1 430 431 432 432.0 432.1 432.9 434 434.0 434.00 434.01 434.1 434.10 434.11 434.9 434.90 434.91 435 435.0 
435.1 435.2 435.3 435.8 435.9 436 437 437.0 437.1 437.2 437.3 437.4 437.5 437.6 437.7 437.8 437.9 
Dementia 1 290 290.0 290.1 290.10 290.11 290.12 290.13 290.2 290.20 290.21 290.3 290.4 290.40 290.41 290.42 290.43 
290.8 290.9 291.2 292.82 294 294.1 294.10 294.11 294.2 294.20 294.21
COPD 1 490 491 491.0 491.1 491.2 491.20 491.21 491.22 491.8 491.9 492 492.0 492.8 
Connective tissue disease 1 517.2 695.4 710 710.0 710.1 710.2 710.3 710.4 710.5 710.8 710.9 714 714.0 714.1 714.2 714.3 714.30 714.31 
714.32 714.33 714.4 714.8 714.81 714.89 714.9 725
Peptic ulcer 1 531 531.0 531.00 531.01 531.1 531.10 531.11 531.2 531.20 531.21 531.3 531.30 531.31 531.4 531.40 531.41 
531.5 531.50 531.51 531.6 531.60 531.61 531.7 531.70 531.71 531.9 531.90 531.91 532 532.0 532.00 532.01 
532.1 532.10 532.11 532.2 532.20 532.21 532.3 532.30 532.31 532.4 532.40 532.41 532.5 532.50 532.51 532.6 
532.60 532.61 532.7 532.70 532.71 532.9 532.90 532.91 533 533.0 533.00 533.01 533.1 533.10 533.11 533.2 
533.20 533.21 533.3 533.30 533.31 533.4 533.40 533.41 533.5 533.50 533.51 533.6 533.60 533.61 533.7 533.70 
533.71 533.9 533.90 533.91 534 534.0 534.00 534.01 534.1 534.10 534.11 534.2 534.20 534.21 534.3 534.30 
534.31 534.4 534.40 534.41 534.5 534.50 534.51 534.6 534.60 534.61 534.7 534.70 534.71 534.9 534.90 534.91
Slight hepatic impairment 1 571.0 571.1 571.40 571.41 571.49 571.5 571.6 571.9 
Diabetes without 
complications
1 249 249.0 249.00 249.01 249.10 249.2 249.20 250.0 250.00 250.01 250.02 250.03 250.20 250.21 250.22 250.23
Diabetes with 
complications
2 249.50 249.60 249.70 250.1 250.10 250.11 250.12 250.13 250.3 250.30 250.31 250.32 250.33 250.4 250.40 250.41 
250.42 250.43 250.5 250.50 250.51 250.52 250.53 250.6 250.60 250.61 250.62 250.63 250.7 250.70 250.71 250.72 
250.73 250.8 250.80 250.81 250.82 250.83 250.9 250.90 250.91 250.92 250.93 357.2 362.01 362.02 362.03 362.04 
362.05 362.06 362.07 366.41. 
Hemiplegia or paraplegia 2 342 342.0 342.00 342.01 342.02 342.1 342.10 342.11 342.12 342.8 342.80 342.81 342.82 342.9 342.90 342.91 
342.92 344.0 344.00 344.01 344.02 344.03 344.04 344.09 344.1 344.2 344.3 344.30 344.31 344.32 344.4 344.40 
344.41 344.42 344.5 438.2 438.20 438.21 438.22 438.3 438.30 438.31 438.32 438.4 438.40 438.41 438.42
Severe or moderate kidney 
disease
2 580.0 580.4 580.8 580.81 580.89 580.9 582 582.0 582.1 582.2 582.4 582.81 582.89 582.9 583 583.0 583.1 583.2 
583.4 583.6 583.7 583.8 583.81 583.89 583.9 585 585.1 585.2 585.3 585.4 585.5 585.6 585.9 586 588 588.0 588.1 
588.8 588.81 588.89 588.9
Nonmetastasized solid tumor 
or leukemia and lymphoma
2 140 140.0 140.1 140.3 140.4 140.5 140.6 140.8 140.9 141 141.0 141.1 141.2 141.3 141.4 141.5141.6 141.8 141.9 
142 142.0 142.1 142.2 142.8 142.9 143 143.0 143.1 143.8 143.9 144 144.0 144.1 144.8 144.9 145 145.0 145.1 
145.2 145.3 145.4 145.5 145.6 145.8 145.9 146 146.0 146.1 146.2 146.3 146.4 146.5 146.6 146.7 146.8 146.9 147 
147.0 147.1 147.2 147.3 147.8 147.9 148 148.0 148.1 148.2 148.3 148.8 148.9 149 149.0 149.1 149.8 149.9 
Severe or moderate hepatic 
impairment
3 456.0 456.1 456.2 456.20 456.21 571.2 571.4 571.42 571.8 572.2 572.3 572.4 572.8 573.5
Metastatic solid tumor 6 196 196.0 196.1 196.2 196.3 196.5 196.6 196.8 196.9 197 197.0 197.1 197.2 197.3 197.4 197.5 197.6 197.7 197.8 
198 198.0 198.1 198.2 198.3 198.4 198.5 198.6 198.7 198.8 198.81 198.82 198.89 199 199.0 199.1 199.2
AIDS 6 “042”
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higher in men (1.11), while for women it was 0.74 and in 
the sample was 0.90.
Multivariate analysis of the diagnoses associated with 
greater disease severity (Charlson ≥5) as a dependent 
variable was performed. All diagnoses were gender, age 
and the number of problems per person adjusted. As can 
be seen in Table 3, the number of conditions per patient 
was the highest predictor of disease severity followed by 
dementia, diabetes, COPD and heart failure in descend-
ing order of OR value. 
The female sex appears to have a protective effect (p < 
0.001; OR 0.807 [0.773–0.842]) and the age risk effect 
(p < 0.001; OR 1.713 [1.703–1.724]).
In the sex-adjusted bivariate analysis by age group (ev-
ery 10 years from the age of 35), the diagnoses associated 
with age (p < 0.001) were as follows:
• Anxiety, liver disease and non-metastatic oncologic 
disease in the adulthood ages (45–54 and 55–64 years 
old).
• Depression, obesity and metastatic oncologic disease 
with the higher OR in the transition age from adult-
hood to old persons (55–64 and 65–74 years old).
• Heart failure, renal failure and dementia OR increas-
ing from 65 years of age onwards until the more ad-
vanced ages (≥95 years old).
• High blood pressure, ischemic coronary disease and 
osteoarthritis associated with all age groups since 55 
years old.
To better understand the behaviour of MM and sever-
ity of disease throughout life, the mean number of prob-
lems and the Charlson index with and without adjust-
ment for age were distributed in the adult population at 
intervals of 5 years from 20 years (Fig. 1).
Table 2. Distribution by age group and sex
Age groups Male % Female % Total Total, %
Young adult (18–39 years) 43,263 26.80 117,971 73.20 161,234 100.00
Adult (40–54 years) 58,930 41.20 84,224 58.80 143,154 100.00
Adult in preretirement (55–64 years) 61,524 49.80 62,018 50.20 123,542 100.00
3rd age (65–74 years) 74,859 51.00 71,783 49.00 146,642 100.00
4th age (75–84 years) 70,507 46.50 81,210 53.50 151,717 100.00
5th age (85+ years) 27,315 36.90 46,772 63.10 74,087 100.00
Total 336,398 42.00 463,978 58.00 800,376 100.00
Table 3. Distribution of the diagnoses associated with the Charlson index ≥5 not age-adjusted in the multivariate 
analysis
Diagnoses p value OR Inferior 
limit
Superior 
limit
Total of medical conditions <0.001 804.571 737.763 877.430
Dementia <0.001 379.468 326.066 441.617
Diabetes <0.001 156.458 143.129 171.028
COPD <0.001 111.830 100.183 124.832
Congestive heart failure <0.001 103.997 94.112 114.921
Nonmetastasized solid tumor or leukemia and lymphoma <0.001 89.627 70.070 114.643
Connective tissue disease <0.001 86.283 73.785 100.897
Peptic ulcer <0.001 70.029 57.713 84.974
Cerebrovascular disease <0.001 64.745 58.290 71.915
Peripheral vascular disease <0.001 40.663 35.344 46.783
Severe or moderate kidney disease <0.001 33.917 29.265 39.308
Ischemic coronary artery disease <0.001 25.338 22.253 28.852
Liver disease <0.001 24.303 20.324 29.062
Hemiplegia or paraplegia <0.001 13.251 11.300 15.540
MM and Disease Severity by Age Groups, 
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As can be seen in Figure 1, the throughout life behav-
iour of the average number of conditions and the average 
Charlson index without adjustment for age are similar. 
The conditions curve is slightly higher than the Charlson 
index average. Both averages begin to rise to 40 years 
reaching the highest value at age 90, the age from which 
a decline is projected. By the weight attributed to age (1 
to group 40 to < 50 years, 2 for 50 to < 60 years, 3 for 60 to 
< 70 and 4 for that of 70 and over), the Charlson index 
age-adjusted shows more sharply the tendency of eleva-
tion after the forty years. 
The distribution by age groups of the age-adjusted 
Charlson index, categorised according to the cut-offs de-
fined in the methodology (cut-off 0 to < 5; cut-off 5 to < 9; 
cut-off ≥9) was represented in Figure 2. Interestingly, for 
the cut-off ≥9, abrupt growth appears at 55/59 years, 
peaking at 75/79 years, while for cut-off 5 at < 9, the most 
marked growth occurs at 65/69 And the peak about 5 
years later than for the cut-off ≥9. For the lower cut-off 
< 5, the decline occurs at 65/69 years. 
When analysing the categories of the Charlson index 
by sex, it was verified that the severity was associated with 
the male sex: cut-off 5 to < 9 (p < 0.001; OR 1.382 [1.368–
1.3897]) and cut-off ≥9 (p < 0.001; OR 1.802 [1.766–
1.838]).
The MM (Fig. 3) analysis was performed for different 
definitions (between 2 or more problems per person 
[MM2 +] to 8 [MM8 +]), which reveals a frequency de-
cline in all age groups when progressing from MM2 + 
to MM8 +: 41.9% (MM2 +), 28.0% (MM3 +), 18.4% 
(MM4 +), 12.4%, 8.8% (MM6 +), 5.0% (MM7 +) and 3.1% 
(MM8 +). If we observe the curves of the different mea-
sures of MM, we can see that they increase up to 90 years 
(64.9% for MM2 + and 46.6% for MM3 +) and up to 85 
for the rest (from MM4 + to MM8 +). In the older ones, 
there is a decline in all different MM measures. 
The 2 definitions of MM (MM2 + and MM3 +) were 
associated with male (OR 1.391 and 1.359, respectively) 
and age (OR 1.056 and 1.052, respectively).
Discussion
The relevant results are similar curve behaviour, by age 
groups, between the mean number of conditions and the 
mean age-adjusted Charlson index, with a curve with the 
onset of growth from the age of 40 years. When the age-
adjusted Charlson index was categorised for different 
cut-offs, there appeared to be 2 severity curves with 10-
year onset elevation. One starting at age 55 for cut-off ≥9 
and another at 65 years for that of 5 to < 9, as well as a peak 
with 5 years difference (at 75 and 80 years, respectively; 
Fig. 2). It, therefore, seems to suggest that the highest dis-
ease severity occurs at middle age group (55–79 years). 
What can justify a study the middle-aged discharged in-
patients with MM are admitted more often than olders 
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Fig. 2. Distribution by age groups of different the Charlson Index cut-off.
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and have similar total hospitalized days per year found in 
a Korean study [14].
The frequency of MM varied according to the mea-
surement considered 41.9% (MM2 +), 28.0% (MM3 +), 
18.4% (MM4 +), 12.4% (MM5 +), 8.8%, 5.0% (MM7 +) 
and 3.1% (MM8 +). Although our results correspond to 
hospitalisation data, these are comparable with those of 
Harrison et al. [3]. However, concerning a study carried 
out in Portugal on primary health care, our frequencies 
were lower [5] probably because they were hospitalisation 
data.
Both of the MM definitions (MM2 + and MM3 +) were 
associated with age and males as in the Portuguese study 
[5] as opposed to a systematic review of Violan et al. [4]. 
It is questioned whether the association with the male 
gender has to do with the data source associated with se-
verity (hospitalisation data), the paradox of using servic-
es related to sex or even the Portuguese population char-
acteristics.
The lifetime frequency curves (Fig. 3) for different def-
initions (from MM2 + to MM8 +) revealed a frequency 
decline in all age groups when progressing from MM2 + 
to MM8 + and elevation between 40 and 90 years for 
MM2 + (64.9%) and MM3 + (46.6%). For the remaining 
definitions (from MM4 + to MM8 +), the increase oc-
curred until the age of 85 years. Although not entirely 
similar, the results confirm the different behaviour of the 
MM prevalence curves throughout the life [3].
One of the highlights of the results of our study was the 
discrimination of the age groups after 75 years, which al-
lowed analysing the nonagenarian population and the de-
cline in the average conditions number and disease sever-
ity. The MM and its severity appear to be associated with 
the middle age groups, from 55 to 79 years. That seems to 
confirm that those who lives longer than after 90 years 
have lower MM. Generating controversy about the MM 
definition, particularly, for the oldest group. 
Limited by the cross-sectional design of the study, we 
still wondered if this group would not be equivalent to the 
healthy group of the DuGoff EH study [7]. Would corre-
spond to those without chronic conditions who lived on 
average 22.6 years [7] or even the permanently healthy 
group of the study by Chang et al. [18].
The validity of the results of our study may derive from 
the robustness conferred by the sample size, the signifi-
cance of the results, the accuracy of the diagnoses and 
their clinical coherence previously mentioned. The use of 
medical records classified according to the ICD is anoth-
er aspect that contributed to the reproducibility and ex-
ternal validation of the results and comparability of mor-
bidity between the different contexts [7].
Our study contemplated 22 chronic health conditions, 
including all, the most frequently studied [19], such as 
diabetes, osteoarthritis, hypertension or cancer, by the 12 
minimum number of medical conditions for MM studies 
suggested in the literature [19]. The generalised linear 
0
10
20
30
40
50
60
70
MM2+ MM3+ MM4+ MM5+ MM6+ MM7+ MM8+
18–19 20–24 25–29 30–34 35–39 40–44 45–49 50–54 55–59 60–64 65–69 70–74 75–79 80–84 85–89 90–94 95–99 100+
Fig. 3. Distribution by age groups of different multimorbidity (MM) definitions.
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model analysis model and the use of the Charlson index 
were other methodological strategies that make our re-
search reproducible.
The identified study limitations were its cross-section-
al design and the hospitalisation nature and provenance 
of the data. In the literature, MM is consistently associated 
with the socioeconomic information such as schooling, 
income or social network, which was missing [4, 6, 20]. 
High educational level, healthy lifestyle, good social net-
work and practicing leisure activities have proved to be 
protective, that is, they attenuate the effect of MM [21] and 
consistent with the well-controlled MM class of Chang’s 
study [18]. However, future research such as longitudinal 
study studies associating the number and nature of medi-
cal conditions and Charlson index over time in different 
contexts (inpatient, primary health care and general pop-
ulation) is in prospect. Other studies and models of analy-
sis should explore the complexity of the MM phenome-
non (social, mental and physical) and clarify the current 
simple and seemingly inadequate definition [7].
The most relevant considered limitation of our re-
search is to use the same medical conditions in both MM 
and severity measures (Charlson index).
The better knowledge of the MM phenomenon and its 
impact on hope and quality of life should also be studied 
[12]. As well as the most successful interventions, in par-
ticular, the paradigm shifts from a traditional disease-ori-
ented approach to a holistic patient centred on the and 
oriented towards the improvement of functional capaci-
ties and quality of life [7, 12].
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